Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.

Journal of acquired immune deficiency syndromes (1999) - 1 Apr 2021

Perez-Valero Ignacio, Llibre Josep M, Castagna Antonella, Pulido Federico, Molina Jean-Michel, Esser Stefan, Margot Nicolas, Shao Yongwu, Temme Lauren, Piontkowsky David, McNicholl Ian R, Haubrich Richard

Abstract excerpt

BACKGROUND: The ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in participants with M184V and/or M184I resistance mutations from historical genotypic reports when switching from a tenofovir disoproxil fumarate-based or abacavir (ABC)-based regimen was investigated. SETTING: Phase IIIb, 48-week, open-label, single-arm, multicenter, clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine
Share to Anti-HIV Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Combinations

Share to Drug Resistance, Viral

Share to Emtricitabine

Share to HIV Infections

Share to Quinolones

Share to Tenofovir

Source

Open in PubMed Open full text

Identifiers

PMID: 33315694
DOI: 10.1097/QAI.0000000000002595
PMCID: PMC7899215

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.PMID 33315694Read ↗

Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.Semantic proximity Read ↗

Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation.Semantic proximity Read ↗

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/ISemantic proximity Read ↗

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/ISemantic proximity Read ↗

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI ResistanceSemantic proximity Read ↗

Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.Semantic proximity Read ↗

Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.Semantic proximity Read ↗

Bictegravir/emtricitabine/tenofovir alafenamide in viremic people with HIV harbouring nucleos(t)ide reverse transcriptase inhibitor resistance-associated mutations.Semantic proximity Read ↗

High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherenceSemantic proximity Read ↗

Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.Semantic proximity Read ↗

Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.Semantic proximity Read ↗

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.